Defining genetic risk factors for scleroderma-associated interstitial lung diseaseIRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease

被引:0
|
作者
Carmel J. W. Stock
Angelo De Lauretis
Dina Visca
Cecile Daccord
Maria Kokosi
Vasilis Kouranos
George Margaritopoulos
Peter M. George
Philip L. Molyneaux
Svetlana Nihtyanova
Felix Chua
Toby M. Maher
Voon Ong
David J. Abraham
Christopher P. Denton
Athol U. Wells
Louise V. Wain
Elisabetta A. Renzoni
机构
[1] Royal Brompton and Harefield NHS Foundation Trust,Interstitial Lung Disease Unit, National Heart and Lung Institute, Imperial College London
[2] Ospedale Guido Salvini,Unita’ Operativa Malattie Respiratorie
[3] Istituti Clinici Scientifici Maugeri,Division of Pulmonary Rehabilitation
[4] IRCCS,Division of Respiratory Medicine
[5] Lausanne University Hospital (CHUV),Centre for Rheumatology and Connective Tissue Diseases
[6] Royal Free and University College Medical School,Department of Health Sciences
[7] University of Leicester,National Institute for Health Research
[8] Leicester Respiratory Biomedical Research Centre,undefined
[9] Glenfield Hospital,undefined
来源
Clinical Rheumatology | 2020年 / 39卷
关键词
Genetic association; Genetics; SSc-ILD;
D O I
暂无
中图分类号
学科分类号
摘要
Although several genetic associations with scleroderma (SSc) are defined, very little is known on genetic susceptibility to SSc-associated interstitial lung disease (SSc-ILD). A number of common polymorphisms have been associated with SSc-ILD, but most have not been replicated in separate populations. Four SNPs in IRF5, and one in each of STAT4, CD226 and IRAK1, selected as having been previously the most consistently associated with SSc-ILD, were genotyped in 612 SSc patients, of European descent, of whom 394 had ILD. The control population (n = 503) comprised individuals of European descent from the 1000 Genomes Project. After Bonferroni correction, two of the IRF5 SNPs, rs2004640 (OR (95% CI)1.30 (1.10–1.54), pcorr = 0.015) and rs10488631 (OR 1.48 (1.14–1.92), pcorr = 0.022), and the STAT4 SNP rs7574865 (OR 1.43 (1.18–1.73), pcorr = 0.0015) were significantly associated with SSc compared with controls. However, none of the SNPs were significantly different between patients with SSc-ILD and controls. Two SNPs in IRF5, rs10488631 (OR 1.72 (1.24–2.39), pcorr = 0.0098), and rs2004640 (OR 1.39 (1.11–1.75), pcorr = 0.03), showed a significant difference in allele frequency between controls and patients without ILD, as did STAT4 rs7574865 (OR 1.86 (1.45–2.38), pcorr = 6.6 × 10−6). A significant difference between SSc with and without ILD was only observed for STAT4 rs7574865, being less frequent in patients with ILD (OR 0.66 (0.51–0.85), pcorr = 0.0084). In conclusion, IRF5 rs2004640 and rs10488631, and STAT4 rs7574865 were significantly associated with SSc as a whole. Only STAT4 rs7574865 showed a significant difference in allele frequency in SSc-ILD, with the T allele being protective against ILD.Key points• We confirm the associations of the IRF5 SNPs rs2004640 and rs10488631, and the STAT4 SNP rs7574865, with SSc as a whole.• None of the tested SNPs were risk factors for SSc-ILD specifically.• The STAT4 rs7574865 T allele was protective against the development of lung fibrosis in SSc patients.• Further work is required to understand the genetic basis of lung fibrosis in association with scleroderma.
引用
下载
收藏
页码:1173 / 1179
页数:6
相关论文
共 50 条
  • [21] Kl-6 As A Predictor Of Progression In Scleroderma-Associated Interstitial Lung Disease
    Watanabe, S.
    Saeki, K.
    Waseda, Y.
    Takato, H.
    Ichikawa, Y.
    Murata, A.
    Hara, J.
    Sone, T.
    Abo, M.
    Kimura, H.
    Yasui, M.
    Kasahara, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [22] The prognostic role of matrix metalloproteinase-7 in scleroderma-associated interstitial lung disease
    Matson, Scott M.
    Lee, Seoyeon J.
    Peterson, Ryan A.
    Achtar-Zadeh, Natalia A.
    Boin, Francesco
    Wolters, Paul J.
    Lee, Joyce S.
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58 (06)
  • [23] MYCOPHENOLATE MOFETIL VERSUS AZATHIOPRINE IN SCLERODERMA-ASSOCIATED INTERSTITIAL LUNG DISEASE: RESULTS FROM THE AUSTRALIAN SCLERODERMA COHORT STUDY
    Owen, C.
    Ngian, G.
    Moore, O.
    Stevens, W.
    Proudman, S.
    Roddy, J.
    Zochling, J.
    Nash, P.
    Hill, C.
    Sturgess, A.
    Sahhar, J.
    INTERNAL MEDICINE JOURNAL, 2014, 44 : 36 - 36
  • [24] THE STABILIZATION OF LUNG FUNCTION IN PATIENTS WITH SCLERODERMA-ASSOCIATED INTERSTITIAL LUNG DISEASE DURING MYCOPHENOLATE MOFETIL THERAPY
    Koneva, O.
    Ananjeva, L.
    Korzeneva, L.
    Alekperov, R.
    Desinova, O.
    Starovoytova, M.
    Nevskaja, T.
    Ovsjannikova, O.
    RHEUMATOLOGY, 2012, 51 : 84 - 84
  • [25] Cyclophosphamide refractory scleroderma-associated interstitial lung disease: dramatic clinical and radiological response to rituximab
    Haroon, M.
    Ryan, J. G.
    Henry, M.
    Harney, S.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2011, 180 : S173 - S173
  • [26] SERUM CYFRA 21-1 AS A PROGNOSTIC MARKER IN SCLERODERMA-ASSOCIATED INTERSTITIAL LUNG DISEASE
    Stock, C. J. W.
    Hoyles, R.
    D'accord, C.
    Kokosi, M.
    Alfieri, V.
    Campochiaro, C.
    Donovan, J.
    Mori, L.
    Maher, T. M.
    Kouranos, V.
    Margaritopoulos, G.
    George, P. M.
    Molyneaux, P. L.
    Chua, F.
    Abraham, D. J.
    Ong, V.
    Denton, C. P.
    Wells, A. U.
    Renzoni, E. A.
    THORAX, 2018, 73 : A89 - A90
  • [28] Evaluation of Efficacy, Immunogenicity, and Toxicity of a Novel Drug Candidate for Scleroderma-associated Interstitial Lung Disease
    Bogatkevich, Galina
    Atanelishvili, Ilia
    Perry, C. Beth
    Silver, Richard
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 2324 - 2325
  • [29] Mycophenolate Mofetil Versus Azathioprine in Scleroderma-Associated Interstitial Lung Disease: Results from the Australian Scleroderma Cohort Study.
    Owen, Claire
    Ngian, Gene
    Elford, Kathleen
    Moore, Owen
    Nikpour, Mandy
    Stevens, Wendy
    Proudman, Susanna
    Roddy, Janet
    Zochling, Jane
    Hill, Catherine
    Nash, Peter
    Sturgess, Allan
    Sahhar, Joanne
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S740 - S741
  • [30] Toupet fundoplication to prevent progression of scleroderma-associated interstitial lung damage: a study protocol
    Aiolfi, Alberto
    Bona, Davide
    Manara, Michele
    Ogliari, Cristina
    Baldessari, Chiara
    Resta, Marco
    Del Papa, Nicoletta
    Cirri, Silvia
    Baisi, Alessandro
    Bonitta, Gianluca
    Sconfienza, Luca
    Harari, Sergio
    Nosotti, Mario
    Vecchi, Maurizio
    Schoppmann, Sebastian F.
    Bonavina, Luigi
    EUROPEAN SURGERY-ACTA CHIRURGICA AUSTRIACA, 2024, 56 (3-4): : 116 - 123